FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562023861> ?p ?o ?g. }

• W2562023861 endingPage "214" @default.
• W2562023861 startingPage "204" @default.
• W2562023861 abstract "•Deviation from high-potency statin therapy is common early in secondary prevention.•Deviation can be by discontinuation, dose reduction, switching, or nonadherence.•Muscular symptoms are associated with suboptimal statin use.•Statin discontinuation/nonadherence is associated with increased adverse outcomes.•Interventions to enhance statin use could improve secondary prevention outcomes. BackgroundHigh-potency statin therapy is recommended in the secondary prevention of cardiovascular disease but discontinuation, dose reduction, statin switching, and/or nonadherence occur in practice.ObjectivesTo determine the prevalence and predictors of deviation from high-potency statin use early after a non-ST elevation acute coronary syndrome (NSTE-ACS) and its association with subsequent major adverse cardiovascular events (MACE) and all-cause mortality (ACM).MethodsA total of 1005 patients from a UK-based prospective NSTE-ACS cohort study discharged on high-potency statin therapy (atorvastatin 80 mg, rosuvastatin 20 mg, or 40 mg daily) were included. At 1 month, patients were divided into constant high-potency statin users, and suboptimal users incorporating statin discontinuation, dose reduction, switching statin to a lower equivalent potency, and/or statin nonadherence. Follow-up was a median of 16 months.ResultsThere were 156 suboptimal (∼15.5%) and 849 constant statin users. Factors associated in multivariable analysis with suboptimal statin occurrence included female sex (odds ratio 1.75, 95% confidence interval [CI] 1.14–2.68) and muscular symptoms (odds ratio 4.28, 95% CI 1.30–14.08). Suboptimal statin use was associated with increased adjusted risks of time to MACE (hazard ratio 2.10, 95% CI 1.25–3.53, P = .005) and ACM (hazard ratio 2.46, 95% CI 1.38–4.39, P = .003). Subgroup analysis confirmed that the increased MACE/ACM risks were principally attributable to statin discontinuation or nonadherence.ConclusionsConversion to suboptimal statin use is common early after NSTE-ACS and is partly related to muscular symptoms. Statin discontinuation or non-adherence carries an adverse prognosis. Interventions that preserve and enhance statin utilization could improve post NSTE-ACS outcomes. High-potency statin therapy is recommended in the secondary prevention of cardiovascular disease but discontinuation, dose reduction, statin switching, and/or nonadherence occur in practice. To determine the prevalence and predictors of deviation from high-potency statin use early after a non-ST elevation acute coronary syndrome (NSTE-ACS) and its association with subsequent major adverse cardiovascular events (MACE) and all-cause mortality (ACM). A total of 1005 patients from a UK-based prospective NSTE-ACS cohort study discharged on high-potency statin therapy (atorvastatin 80 mg, rosuvastatin 20 mg, or 40 mg daily) were included. At 1 month, patients were divided into constant high-potency statin users, and suboptimal users incorporating statin discontinuation, dose reduction, switching statin to a lower equivalent potency, and/or statin nonadherence. Follow-up was a median of 16 months. There were 156 suboptimal (∼15.5%) and 849 constant statin users. Factors associated in multivariable analysis with suboptimal statin occurrence included female sex (odds ratio 1.75, 95% confidence interval [CI] 1.14–2.68) and muscular symptoms (odds ratio 4.28, 95% CI 1.30–14.08). Suboptimal statin use was associated with increased adjusted risks of time to MACE (hazard ratio 2.10, 95% CI 1.25–3.53, P = .005) and ACM (hazard ratio 2.46, 95% CI 1.38–4.39, P = .003). Subgroup analysis confirmed that the increased MACE/ACM risks were principally attributable to statin discontinuation or nonadherence. Conversion to suboptimal statin use is common early after NSTE-ACS and is partly related to muscular symptoms. Statin discontinuation or non-adherence carries an adverse prognosis. Interventions that preserve and enhance statin utilization could improve post NSTE-ACS outcomes." @default.
• W2562023861 created "2017-01-06" @default.
• W2562023861 creator A5006847944 @default.
• W2562023861 creator A5025775908 @default.
• W2562023861 creator A5025786528 @default.
• W2562023861 creator A5047395227 @default.
• W2562023861 creator A5047661674 @default.
• W2562023861 creator A5077672453 @default.
• W2562023861 creator A5080862674 @default.
• W2562023861 creator A5081583489 @default.
• W2562023861 date "2017-01-01" @default.
• W2562023861 modified "2023-09-26" @default.
• W2562023861 title "Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome" @default.
• W2562023861 cites W116577846 @default.
• W2562023861 cites W183239856 @default.
• W2562023861 cites W1948458971 @default.
• W2562023861 cites W1972221358 @default.
• W2562023861 cites W1982914740 @default.
• W2562023861 cites W1988872621 @default.
• W2562023861 cites W1989584814 @default.
• W2562023861 cites W2010033213 @default.
• W2562023861 cites W2017509671 @default.
• W2562023861 cites W2034776370 @default.
• W2562023861 cites W2035681453 @default.
• W2562023861 cites W2041281891 @default.
• W2562023861 cites W2045042595 @default.
• W2562023861 cites W2058647728 @default.
• W2562023861 cites W2066660801 @default.
• W2562023861 cites W2069818772 @default.
• W2562023861 cites W2079972091 @default.
• W2562023861 cites W2081238165 @default.
• W2562023861 cites W2097319856 @default.
• W2562023861 cites W2097648921 @default.
• W2562023861 cites W2110406725 @default.
• W2562023861 cites W2113320440 @default.
• W2562023861 cites W2118061083 @default.
• W2562023861 cites W2118418912 @default.
• W2562023861 cites W2122857025 @default.
• W2562023861 cites W2129124334 @default.
• W2562023861 cites W2134159541 @default.
• W2562023861 cites W2136893214 @default.
• W2562023861 cites W2143003213 @default.
• W2562023861 cites W2153205212 @default.
• W2562023861 cites W2154735184 @default.
• W2562023861 cites W2157318918 @default.
• W2562023861 cites W2158572075 @default.
• W2562023861 cites W2159449551 @default.
• W2562023861 cites W2164162488 @default.
• W2562023861 cites W2171656437 @default.
• W2562023861 cites W2396620104 @default.
• W2562023861 cites W2519634482 @default.
• W2562023861 cites W34488919 @default.
• W2562023861 cites W4378421171 @default.
• W2562023861 cites W98219914 @default.
• W2562023861 doi "https://doi.org/10.1016/j.jacl.2016.12.007" @default.
• W2562023861 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5399750" @default.
• W2562023861 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28391887" @default.
• W2562023861 hasPublicationYear "2017" @default.
• W2562023861 type Work @default.
• W2562023861 sameAs 2562023861 @default.
• W2562023861 citedByCount "19" @default.
• W2562023861 countsByYear W25620238612017 @default.
• W2562023861 countsByYear W25620238612018 @default.
• W2562023861 countsByYear W25620238612019 @default.
• W2562023861 countsByYear W25620238612020 @default.
• W2562023861 countsByYear W25620238612021 @default.
• W2562023861 countsByYear W25620238612022 @default.
• W2562023861 countsByYear W25620238612023 @default.
• W2562023861 crossrefType "journal-article" @default.
• W2562023861 hasAuthorship W2562023861A5006847944 @default.
• W2562023861 hasAuthorship W2562023861A5025775908 @default.
• W2562023861 hasAuthorship W2562023861A5025786528 @default.
• W2562023861 hasAuthorship W2562023861A5047395227 @default.
• W2562023861 hasAuthorship W2562023861A5047661674 @default.
• W2562023861 hasAuthorship W2562023861A5077672453 @default.
• W2562023861 hasAuthorship W2562023861A5080862674 @default.
• W2562023861 hasAuthorship W2562023861A5081583489 @default.
• W2562023861 hasBestOaLocation W25620238611 @default.
• W2562023861 hasConcept C126322002 @default.
• W2562023861 hasConcept C156957248 @default.
• W2562023861 hasConcept C188816634 @default.
• W2562023861 hasConcept C207103383 @default.
• W2562023861 hasConcept C2776839432 @default.
• W2562023861 hasConcept C2777482532 @default.
• W2562023861 hasConcept C2777698277 @default.
• W2562023861 hasConcept C2778715236 @default.
• W2562023861 hasConcept C2780400711 @default.
• W2562023861 hasConcept C2780499067 @default.
• W2562023861 hasConcept C2780739214 @default.
• W2562023861 hasConcept C44249647 @default.
• W2562023861 hasConcept C500558357 @default.
• W2562023861 hasConcept C71924100 @default.
• W2562023861 hasConceptScore W2562023861C126322002 @default.
• W2562023861 hasConceptScore W2562023861C156957248 @default.
• W2562023861 hasConceptScore W2562023861C188816634 @default.
• W2562023861 hasConceptScore W2562023861C207103383 @default.
• W2562023861 hasConceptScore W2562023861C2776839432 @default.
• W2562023861 hasConceptScore W2562023861C2777482532 @default.

• next